Companies will work together to bring rapid
antimicrobial identification and susceptibility diagnostics to more
clinicians and patients worldwide
FRANKLIN
LAKES, N.J. and TUCSON,
Ariz., Aug. 15, 2022 /PRNewswire/ -- BD (Becton,
Dickinson and Company) (NYSE: BDX), a leading global medical
technology company, and Accelerate Diagnostics, Inc. (NASDAQ: AXDX)
an innovator of rapid in-vitro diagnostics in microbiology, today
announced a worldwide commercial collaboration agreement where BD
will offer Accelerate's rapid testing solution for antibiotic
resistance and susceptibility offering results in hours, versus one
to two days with some traditional laboratory methods.
Under the agreement, BD will market and sell the Accelerate
Pheno® system and Accelerate Arc™ module and associated
test kits through its global sales network in territories where
products have regulatory approval or registration. These solutions
complement BD's existing Clinical Microbiology portfolio and
advance the shared goal of both companies to address the global
threat of antimicrobial resistance.
"When a patient is very sick, every minute matters," said
Brooke Story, president of
Integrated Diagnostic Solutions for BD. "Rapid testing can quickly
determine if an antibiotic should be used for treatment, and if so,
which one. Through our collaboration with Accelerate Diagnostics,
we can help clinicians more quickly, efficiently and effectively
treat patients, which may lead to a reduction in health care costs
and help slow the spread of antimicrobial resistance."
The Accelerate PhenoTest® BC kit is the first test
cleared by the U.S. Food and Drug Administration that can deliver
both rapid identification and phenotypic antibiotic susceptibility
results in hours direct from positive blood cultures. Recent
external studies indicate this solution offers results one to two
days faster than traditional laboratory methods, which can include
culturing samples for 18 to 24 hours, and then performing a
susceptibility test that can take eight to 24 hours to result. This
enables clinicians to optimize antibiotic selection and dosage
specific to the individual patient, days earlier. It is well
established in peer-reviewed literature that improving time to
optimal therapy benefits both patient outcomes and hospital
operations.
The Accelerate Arc™ module is a simple load-and-go system that
eliminates the requirement of a subculture for MALDI ID as well as
the need for lengthy hands-on time by automating the direct MALDI
ID workflow. It is currently US , CE-IVDR and UKCA registered for
positive blood cultures.
"With BD's large installed customer base of clinical
microbiology systems, this collaboration exponentially increases
our global commercial reach and provides numerous ways to increase
our market penetration with Pheno and Arc to reach more clinicians
and patients," said Jack Phillips,
president and CEO of Accelerate Diagnostics. "Beyond the immediate
clinical and commercial benefits, we are excited about the
opportunity to collaborate with BD as a long-term leader in
clinical microbiology."
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company
dedicated to providing solutions for the global challenges of
antibiotic resistant infections, a leading cause of sepsis. The
company's first fully automated platform to provide rapid
identification and antimicrobial susceptibility results remains the
only solution currently cleared for use with positive blood culture
samples by the U.S. FDA.
For more information about the company, its products and
technology, or recent publications, visit axdx.com.
About BD
BD is one of the largest global medical technology companies in
the world and is advancing the world of health by improving medical
discovery, diagnostics, and the delivery of care. The company
supports the heroes on the frontlines of health care by developing
innovative technology, services and solutions that help advance
both clinical therapy for patients and clinical process for health
care providers. BD and its 75,000 employees have a passion and
commitment to help enhance the safety and efficiency of clinicians'
care delivery process, enable laboratory scientists to accurately
detect disease and advance researchers' capabilities to develop the
next generation of diagnostics and therapeutics. BD has a presence
in virtually every country and partners with organizations around
the world to address some of the most challenging global health
issues. By working in close collaboration with customers, BD can
help enhance outcomes, lower costs, increase efficiencies, improve
safety and expand access to health care. For more information on
BD, please visit bd.com or connect with us on LinkedIn at
www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Contacts
Media
Troy
Kirkpatrick
VP, Public
Relations
858.617.2361
troy.kirkpatrick@bd.com
|
Investors
Francesca
DeMartino
SVP, Head of Investor
Relations
201.847.5743
francesca.demartino@bd.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bd-accelerate-diagnostics-announce-global-commercial-collaboration-301605434.html
SOURCE BD (Becton, Dickinson and Company)